- Home
- HE vs EWTX Comparison
HE vs EWTX Comparison
Compare HE & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HE
- EWTX
- Stock Information
- Founded
- HE 1891
- EWTX 2017
- Country
- HE United States
- EWTX United States
- Employees
- HE N/A
- EWTX N/A
- Industry
- HE Electric Utilities: Central
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- HE Utilities
- EWTX Health Care
- Exchange
- HE Nasdaq
- EWTX Nasdaq
- Market Cap
- HE 2.0B
- EWTX 1.6B
- IPO Year
- HE N/A
- EWTX 2021
- Fundamental
- Price
- HE $11.66
- EWTX $17.27
- Analyst Decision
- HE Hold
- EWTX Buy
- Analyst Count
- HE 4
- EWTX 10
- Target Price
- HE $10.94
- EWTX $37.90
- AVG Volume (30 Days)
- HE 1.5M
- EWTX 842.1K
- Earning Date
- HE 11-07-2025
- EWTX 11-06-2025
- Dividend Yield
- HE N/A
- EWTX N/A
- EPS Growth
- HE N/A
- EWTX N/A
- EPS
- HE N/A
- EWTX N/A
- Revenue
- HE $3,122,881,000.00
- EWTX N/A
- Revenue This Year
- HE $12.58
- EWTX N/A
- Revenue Next Year
- HE $2.10
- EWTX N/A
- P/E Ratio
- HE N/A
- EWTX N/A
- Revenue Growth
- HE 2.36
- EWTX N/A
- 52 Week Low
- HE $8.14
- EWTX $10.60
- 52 Week High
- HE $13.41
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- HE 52.42
- EWTX 59.41
- Support Level
- HE $11.33
- EWTX $16.82
- Resistance Level
- HE $11.71
- EWTX $18.78
- Average True Range (ATR)
- HE 0.28
- EWTX 0.93
- MACD
- HE -0.00
- EWTX 0.15
- Stochastic Oscillator
- HE 40.83
- EWTX 68.09
About HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.